SCR-LIP-000471 · Claim · machine-readable JSON →

This narrative review describes lipedema tissue inflammation as chronic low-grade immune dysfunction with increased CD45+, CD68+, and CD163+ immune cell infiltration and M2 macrophage predominance, and characterizes pain as multifactorial — driven by microvascular dysfunction, chronic inflammation, increased interstitial pressure compressing peripheral nerves, neuroinflammatory processes, altered sympathetic signaling, and micro-neuropathic changes rather than mechanical load or obesity alone.

This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
very low (GRADE)
Evidence
1 source(s)
Dates
2026-11-17 → 2026-11-17

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17

Evidence over time

2026Lipedema: pathophysiological insights and therapeutic strategies — An update for dermatologists (2026) · consistent

Evidence (1)

Context (PECO)

Populationpatients with lipedema (narrative review synthesis)
Conditionlipedema
Exposurelipedema adipose tissue inflammation and pain pathophysiology
Outcomeimmune cell infiltration, macrophage phenotype, and pain mechanisms
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log